JP2014530803A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530803A5
JP2014530803A5 JP2014523434A JP2014523434A JP2014530803A5 JP 2014530803 A5 JP2014530803 A5 JP 2014530803A5 JP 2014523434 A JP2014523434 A JP 2014523434A JP 2014523434 A JP2014523434 A JP 2014523434A JP 2014530803 A5 JP2014530803 A5 JP 2014530803A5
Authority
JP
Japan
Prior art keywords
mir
nucleic acid
precursor
modified
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014523434A
Other languages
English (en)
Japanese (ja)
Other versions
JP6309450B2 (ja
JP2014530803A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/053971 external-priority patent/WO2013018060A2/en
Publication of JP2014530803A publication Critical patent/JP2014530803A/ja
Publication of JP2014530803A5 publication Critical patent/JP2014530803A5/ja
Application granted granted Critical
Publication of JP6309450B2 publication Critical patent/JP6309450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014523434A 2011-08-04 2012-08-02 セロトニン関連の医学的状態、アドレナリン関連の医学的状態、ノルアドレナリン関連の医学的状態、グルタミン酸関連の医学的状態および副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのミクロｒｎａおよび該ミクロｒｎａを含む組成物 Active JP6309450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161514954P 2011-08-04 2011-08-04
US61/514,954 2011-08-04
PCT/IB2012/053971 WO2013018060A2 (en) 2011-08-04 2012-08-02 Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016254743A Division JP2017095482A (ja) 2011-08-04 2016-12-28 セロトニン関連の医学的状態、アドレナリン関連の医学的状態、ノルアドレナリン関連の医学的状態、グルタミン酸関連の医学的状態および副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのミクロｒｎａおよび該ミクロｒｎａを含む組成物

Publications (3)

Publication Number Publication Date
JP2014530803A JP2014530803A (ja) 2014-11-20
JP2014530803A5 true JP2014530803A5 (OSRAM) 2015-07-09
JP6309450B2 JP6309450B2 (ja) 2018-04-11

Family

ID=46875925

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014523434A Active JP6309450B2 (ja) 2011-08-04 2012-08-02 セロトニン関連の医学的状態、アドレナリン関連の医学的状態、ノルアドレナリン関連の医学的状態、グルタミン酸関連の医学的状態および副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのミクロｒｎａおよび該ミクロｒｎａを含む組成物
JP2016254743A Pending JP2017095482A (ja) 2011-08-04 2016-12-28 セロトニン関連の医学的状態、アドレナリン関連の医学的状態、ノルアドレナリン関連の医学的状態、グルタミン酸関連の医学的状態および副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのミクロｒｎａおよび該ミクロｒｎａを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016254743A Pending JP2017095482A (ja) 2011-08-04 2016-12-28 セロトニン関連の医学的状態、アドレナリン関連の医学的状態、ノルアドレナリン関連の医学的状態、グルタミン酸関連の医学的状態および副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのミクロｒｎａおよび該ミクロｒｎａを含む組成物

Country Status (10)

Country Link
US (5) US9150858B2 (OSRAM)
EP (3) EP2739736B1 (OSRAM)
JP (2) JP6309450B2 (OSRAM)
CN (3) CN107115352B (OSRAM)
BR (1) BR112014002737B1 (OSRAM)
CA (2) CA2844012C (OSRAM)
ES (2) ES2732427T3 (OSRAM)
HU (2) HUE033746T2 (OSRAM)
IL (1) IL230814A (OSRAM)
WO (1) WO2013018060A2 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018060A2 (en) 2011-08-04 2013-02-07 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
CN105934439B (zh) 2013-11-27 2019-09-10 西格马-奥尔德里奇有限责任公司 从生物流体中分离微小rna
CN106715695B (zh) * 2014-02-05 2020-07-31 耶达研究及发展有限公司 用于治疗和诊断的微rna和包含所述微rna的组合物
EP3134552B1 (en) * 2014-04-22 2020-11-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods, processes, devices and kits for the measurement of post traumatic stress disorder microrna markers
CN107078202B (zh) * 2014-10-09 2019-07-19 德尔塔蒂研究财团 一种集成热电发电机
CN104826131B (zh) * 2015-04-15 2018-12-18 涛康生物科技（上海）有限公司 miR-17-92基因簇在制备治疗精神类疾病药物中的用途
CN105349643B (zh) * 2015-11-05 2018-09-07 中国航天员科研训练中心 预测睡眠剥夺后5-羟色胺变化的方法与microRNAs标志物
WO2017087726A1 (en) * 2015-11-18 2017-05-26 Dignity Health Methods of diagnosing epilepsy
CN105709240B (zh) * 2016-03-23 2020-07-07 中国人民解放军第四军医大学 一种miR-26a抑制剂及其应用
CN105748501B (zh) * 2016-03-31 2017-07-28 成都仕康美生物科技有限公司 一种miRNA‑182抑制剂及其在制备防治心脏移植免疫排斥反应药物中的应用
CN111566212A (zh) 2017-11-03 2020-08-21 因特尔纳技术有限公司 miRNA分子，等同物，安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
AU2019237514A1 (en) 2018-03-23 2020-10-08 University Of Massachusetts Gene therapeutics for treating bone disorders
CA3019970A1 (en) * 2018-10-05 2020-04-05 Fang Liu Methods for diagnosing or treating post-traumatic stress disorder, and compositions therefor
CN112852961B (zh) * 2021-01-08 2022-09-13 上海市胸科医院 肺腺癌铁死亡敏感性标志物adcy10及其应用
CN113897435B (zh) * 2021-11-22 2024-08-06 山西农业大学 一种用于评估黑色素瘤转移风险的miRNA及其应用
JPWO2023182507A1 (OSRAM) * 2022-03-24 2023-09-28
WO2024020376A1 (en) * 2022-07-22 2024-01-25 University Of Massachusetts Aav-mediated delivery of osteoblast/osteoclast-regulating mirnas for osteoporosis therapy

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
WO1989009221A1 (en) 1988-03-25 1989-10-05 University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
PT98562B (pt) 1990-08-03 1999-01-29 Sanofi Sa Processo para a preparacao de composicoes que compreendem sequencias de nucleo-sidos com cerca de 6 a cerca de 200 bases resistentes a nucleases
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
AU662298B2 (en) 1990-09-20 1995-08-31 Gilead Sciences, Inc. Modified internucleoside linkages
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
ATE160572T1 (de) 1993-03-31 1997-12-15 Sanofi Sa Oligonucleotide mit amidverkettungen die phosphoesterverkettungen einsetzen
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US6303374B1 (en) 2000-01-18 2001-10-16 Isis Pharmaceuticals Inc. Antisense modulation of caspase 3 expression
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
ES2534302T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
HUE027013T2 (en) * 2005-05-27 2016-10-28 Ospedale San Raffaele Srl A gene vector containing MI-RNA
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CN101296702B (zh) * 2005-09-12 2012-11-28 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
EP2369012A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
US20090307788A1 (en) * 2006-06-19 2009-12-10 Kobenhavns Universitet Ribozyme mediated stabilization of polynucleotides
CA2663962A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20090306181A1 (en) * 2006-09-29 2009-12-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
US20090092980A1 (en) * 2007-07-20 2009-04-09 Christoph Arenz miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES
ES2617877T3 (es) 2007-08-27 2017-06-20 1Globe Health Institute Llc Composiciones de ARN interferente asimétrico y uso de las mismas
US7993831B2 (en) * 2007-09-14 2011-08-09 Asuragen, Inc. Methods of normalization in microRNA detection assays
EP2235175A4 (en) 2007-12-20 2012-04-25 Angiochem Inc POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF
EP2298359A1 (en) 2008-06-04 2011-03-23 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of controlling degranulation of mast cell
WO2010048123A2 (en) 2008-10-20 2010-04-29 Eckhardt S Gail Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2009217433A1 (en) * 2009-03-05 2010-09-23 Newcastle Innovation Limited Diagnostic, prognostic and treatment methods
EP2416789B1 (en) * 2009-04-07 2017-06-21 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
JP2012525146A (ja) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
CN101590243A (zh) * 2009-06-23 2009-12-02 暨南大学 微小rna在制备治疗和/或预防淋巴瘤药物中的应用
DK2560687T3 (en) 2010-04-19 2017-09-18 Nlife Therapeutics S L Preparations and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
EP3075396A1 (en) 2010-10-17 2016-10-05 Yeda Research and Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
WO2013018060A2 (en) 2011-08-04 2013-02-07 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2013116589A1 (en) 2012-02-02 2013-08-08 St. Jude Children's Research Hospital Methods for diagnosing and treating learning or mental disorders
JP2016503394A (ja) 2012-10-26 2016-02-04 エヌライフ、セラピューティックス、ソシエダッド、リミターダＮｌｉｆｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｓ．Ｌ． 細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法
MX2015005352A (es) 2012-10-26 2015-10-29 Nlife Therapeutics S L Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas.
CN106715695B (zh) 2014-02-05 2020-07-31 耶达研究及发展有限公司 用于治疗和诊断的微rna和包含所述微rna的组合物
JP2024503711A (ja) 2021-01-18 2024-01-26 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 修飾ｍｉＲ－１３５、そのコンジュゲートおよびその使用

Similar Documents

Publication Publication Date Title
JP2014530803A5 (OSRAM)
Schuster et al. Antiviral RNAi in insects and mammals: parallels and differences
Huang et al. Mechanobiology of periodontal ligament stem cells in orthodontic tooth movement
WO2009036933A3 (de) Herabregulation der genexpression mittels nukleinsäure-beladener virusähnlicher partikel
JP2013529909A5 (OSRAM)
WO2012145601A3 (en) Adeno-associated virus virions with variant capsid and methods of use thereof
Ho et al. MicroRNA and pathogenesis of enterovirus infection
JP2012519484A5 (OSRAM)
Heaton Harnessing host–virus evolution in antiviral therapy and immunotherapy
JP2017506228A5 (OSRAM)
CN109843914A (zh) 用于治疗疼痛相关病症的材料和方法
JP2016520310A5 (OSRAM)
NZ587060A (en) Rna interference for the treatment of heart failure
JP2015502365A5 (OSRAM)
WO2009132656A3 (en) Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
RU2015155332A (ru) Олигонуклеотидные модуляторы в-клеточной cll/лимфомы 11а (bcl11а) и их применение
JP2014520072A5 (OSRAM)
JP2010512747A5 (OSRAM)
Luczo et al. Evolution of high pathogenicity of H5 avian influenza virus: haemagglutinin cleavage site selection of reverse-genetics mutants during passage in chickens
RU2011108196A (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРРОЛОХИНОЛИНОХИНОНА (PQQ) С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ РОДА Methylobacterium ИЛИ Hyphomicrobium
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
Wulff et al. Substitutional A‐to‐I RNA editing
Hu et al. Upregulated TSG‐6 Expression in ADSCs Inhibits the BV2 Microglia‐Mediated Inflammatory Response
WO2012135600A3 (en) Gall wasp control agents
JP2013531491A5 (OSRAM)